NCI will form an ad hoc committee to review screening trials

The future of ECOG-ACRIN's slowly-accruing TMIST is in question

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NCI’s cancer screening trials may be falling victim to the COVID-19 pandemic.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Paul Goldberg
Editor & Publisher

YOU MAY BE INTERESTED IN

When conducting a randomized clinical trial of a treatment regimen based on an immune checkpoint inhibitor, trial sponsors should include overall survival as an endpoint, FDA officials say.
Paul Goldberg
Editor & Publisher

Login